Silicon Valley 'pain index' shows growing gap between wealthy
The report is called the "Silicon Valley Pain Index," because the goal is to measure poverty, inequality and the suffering this can cause.
SJSU researchers used more than 200 data points and statistics to put together the report.
One of the more startling figures is the fact that more than 70 percent of the wealth in Silicon Valley is concentrated in just nine households.
Those nine households made $136 billion more last year alone than they did the year before.
Compare that to at least 100,000 households in Santa Clara County with absolutely no assets at all.
The authors of the report say the wealth gap in the region has grown, and this extreme income disparity leads to all kinds of problems, especially when it comes to food, education and housing.
The report says the average person needs to make at least $125,000 a year to be able to afford San Jose's average $3,200-a-month rent.
And that a lack of affordable housing has created a domino effect - with families leaving the area, leading to lower enrollment in schools, and school closures.
It also means a shortage of workers for essential jobs.
The report's authors say San Jose would have to build about 8,000 new homes every year to reach its long-term housing goals.
The most the city has ever built in a year is about 1,700 homes.
There are some positive changes the report highlighted - including a decline in police use-of-force incidents in San Jose last year; fewer carbon emissions and pollution; and expanded homeless services in the community last year.
The authors of the study say they hope it leads to policy changes amd changes in behavior among the wealthiest individuals.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
24 minutes ago
- Forbes
Former Citigroup Chair Sandy Weill's New $100 Million Gift To Harness AI For A West Coast Cancer Hub
Philanthropists Joan and Sandy Weill Walter Zarnowitz/UCSF S anford 'Sandy' Weill, the former CEO and chairman of banking giant Citigroup, and his wife Joan have been big donors to medical research on both coasts of the U.S. Now, the couple are taking it up a notch. On Wednesday, two Bay Area universities–University of California, San Francisco and Stanford University–announced a $100 million gift over 10 years from the Weill Family Foundation for a new cancer hub that is designed to advance cancer research and treatment via four specific projects. The gift, a matching grant, has the goal of raising an additional $100 million for the new initiative, called the Weill Cancer Hub West. A quarter of the matching funds have already been raised, the universities said. 'I think the time for cancer is now,' Sam Hawgood, UC San Francisco's chancellor, tells Forbes . Hawgood cites advances in technology and cancer research including advanced computation and the ability to sequence the genomes of single cells at scale. 'Those kinds of tools open up a whole new opportunity space–and the space is almost too big for any single university.' Though the death rate from cancer has fallen by about a third in the past quarter century–partly due these better tools, cancer is still on the rise, with almost 20 million new cases annually and about 10 million deaths globally each year. Sandy Weill, who retired as Citigroup CEO in 2003 and as chairman in 2006 and dropped off Forbes' billionaires list in 2022 as a result of his charitable giving, is now age 92 and devoting most of his time to philanthropy via he and Joan's $425 million (assets) charitable foundation. He's a big fan of collaborative research. 'When people are willing to partner and collaborate with other bright people, you get a much better chance of coming to a solution,' Weill said in an interview at his home in Sonoma, California last week. The Weill Cancer Hub West will harness recent promising developments to tackle cancer. One project will use the gene editing tool CRISPR to engineer immune cells inside the body by injecting the CRISPR machinery into a patient, deliver it to a patient's immune cells, and reprogram those cells to go after the cancer. Jennifer Doudna, the UC Berkeley biochemist who shared the Nobel prize in chemistry 2020 for the CRISPR gene editing breakthrough, will participate in this research effort as well. Another project, in the area of cellular therapy, aims to build weaponized cells that are personalized to each patient to go after solid tumors–like breast cancer or pancreatic cancer. To date, this kind of cellular therapy has shown results in liquid tumors that circulate in the blood stream, in cancers like leukemia and lymphoma, but not yet in solid tumors. 'We haven't begun to scratch the surface of how we engineer cells' for this kind of treatment, says Dr. Crystal Mackall, the founding director of Stanford's Center for Cancer Cell Therapy. Mackall will co-lead this project with UCSF immunology and microbiology professor Kole Roybal. A third project will investigate the links between cancer, diet and drugs–including the very popular weight loss drugs called GLP-1 agonists (like Ozempic and Wegovy). Anecdotal information has shown a reduction in cancer by those taking the weight loss drugs, possibly because of reduced inflammation, says Alan Ashworth, president of UCSF's cancer care center. The group will also study whether different diets, like a ketogenic diet, can slow cancer progression. The fourth project will harness AI to examine anonymized patient medical records, imaging data, genetic tests and more to try and help determine the best treatments for an individual patient. This will be particularly helpful for guiding treatment, for example, for the third or fourth set of drugs (also called third- or fourth-line treament)–for patients with colorectal cancer, where there is no established standard, says Ashworth. Stanford physician and immunologist Crystal Mackall is co-leading the team creating cellular therapies designed to go after solid tumors, which account for more than 90% of all cancers. Stanford University Health Care 'We're embracing risk in this. Now these projects are not going to fail in the sense they're not going to discover things. But what we've got are stretch goals,' adds Ashworth. The planning for how the Weill's gift would be used has been in the works for two years. In December 2023, researchers from the two universities held a symposium to talk about what might be possible. 'We came away thinking this is going to be really transformative,' says Lloyd Minor, dean of Stanford's medical school and vice president for medical affairs at Stanford. Faculty members had the opportunity to submit a research proposal, and the projects were selected in an open competition. Minor expects to begin seeing the fruits of the research–improvements in cancer diagnosis, treatment and prevention–in a matter of years. 'What we've witnessed over the past 15 years is a dramatic acceleration in the translation of science from the bench to improvements in therapies for patients,' says Minor, noting the rapid development of immunotherapy drugs called checkpoint inhibitors—that block a protein cancer uses to evade the immune system. The best known of these is a Merck's drug Keytruda. The Weills are betting that the collaborative work will yield results. Back in 2019, the couple launched the Weill Neurohub with a promise of $106 million in funding for collaborative neuroscience research by scientists at UC Berkeley, UC San Francisco, the University of Washington and the Allen Institute in Seattle, founded by the late Microsoft cofounder Paul Allen. In March this year, the Weills promised $50 million in funding to the newly-created Weill Cancer Hub East, a collaborative undertaking between Cornell University's Weill Cornell Medicine, Princeton University, Rockefeller University and the Ludwig Institute for Cancer Research. A number of billionaire donors have also embraced collaborative research, including Facebook founder Mark Zuckerberg and his wife Priscilla Chan, who launched their first Chan Zuckerberg Biohub in San Francisco in 2016 with a promised $600 million in funding. The biohub links researchers and engineers from UC Berkeley, UC San Francisco and Stanford; the couple have since launched additional biohubs in Chicago and New York. Sean Parker, who built a fortune as the (brief) first president of Facebook, launched the Parker Institute for Cancer Immunotherapy in 2016 with $250 million in seed funding; its research network includes seven universities or research centers including Stanford, UC San Francisco, and Weill Cornell Medicine. Google founder Sergey Brin has put more than $1.75 billion toward research of Parkinson's disease; his Aligning Science Across Parkinson's group, or ASAP, funds collaborative research at university labs around the world. And Stripe cofounder Patrick Collison was a key cofounder of the Arc Institute in 2021, which collaborates with Stanford, UC San Francisco and UC Berkeley. As for the Weil Cancer Hub West, expectations are high. Says Stanford's Mackall, 'This gift–with a capital G– is going to allow us to keep our foot on the gas and not let up because of other funding challenges.' More from Forbes Forbes Why JPMorgan Is Hitting Fintechs With Stunning New Fees For Data Access By Jeff Kauflin Forbes Go Back To The Office, But Bring Your Own Snacks. Blame Congress. By Kelly Phillips Erb Forbes The Best Places To Retire Abroad In 2025 By William P. Barrett Forbes Inside America's Top Small Business Bank By Brandon Kochkodin Forbes You're Not Imagining It: AI Is Already Taking Tech Jobs By Richard Nieva
Washington Post
24 minutes ago
- Washington Post
Live updates: White House to brief reporters as uproar over Epstein files upends Washington
White House press secretary Karoline Leavitt has scheduled a news briefing Wednesday amid the continued controversy over the Trump administration's decision not to release files related to deceased sex offender Jeffrey Epstein. The House is expected to adjourn Wednesday, a day earlier than expected, for its five-week recess after Republicans irate over the administration's decision blocked most legislation from reaching the chamber floor for a vote this week. President Donald Trump, who has sought to change the subject, plans Wednesday to deliver a speech on artificial intelligence and unveil three executive orders intended to boost the U.S. tech sector. Silicon Valley's risky bet on President Donald Trump is starting to pay dividends. The White House on Wednesday plans to reveal how it will position the United States to lead a global race to develop artificial intelligence and unveil three executive orders intended to boost the American tech sector, according to two people familiar with the rollout who spoke on the condition of anonymity to discuss plans that have not been made public. Former president Barack Obama's office issued a rare admonishment Tuesday of the Trump administration's claims that Obama administration officials planned a 'treasonous conspiracy' aimed at the current commander in chief, calling the allegations 'a weak attempt at distraction.' President Donald Trump said Tuesday he has clinched a trade deal with Japan, reducing the tariffs he had planned to impose on goods from a major trading partner as his deadline for negotiations nears. Trump posted on his Truth Social social media site Tuesday evening that he would impose a 15 percent duty on Japanese imports, down from the 25 percent he threatened earlier this month. Federal judges in New Jersey declined Tuesday to appoint Alina Habba, President Donald Trump's pick for U.S. attorney in the state, to continue serving in that role, delivering a resounding rebuke to one of his administration's most polarizing Justice Department appointees and teeing up a showdown over who would lead the office. A panel of the state's U.S. district court judges made the announcement in a brief order that did not offer any explanation for its decision.
Yahoo
an hour ago
- Yahoo
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-person and virtual R&D Day on September 8, 2025 from 8:00am to 10:00am ET in New York City to present multiple clinical data updates across the pipeline and highlight the next key drivers of growth and upcoming milestones. "This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data updates across our potential first-in-class pipeline, and highlight our strategic vision, priority areas of scientific focus, and emerging clinical pipeline that will drive the next phase of our growth as a global leader in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. Speakers will include members of IDEAYA's senior leadership team and key opinion leader(s). Registration for this event can be accessed here or at the investors section of the IDEAYA website at About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025. Investor and Media Contact IDEAYA BiosciencesJoshua Bleharski, Financial Officer investor@ View original content to download multimedia: SOURCE IDEAYA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
